| Literature DB >> 33019547 |
Nedim Durmus1, Yongzhao Shao2,3,4, Alan A Arslan2,3,5,6, Yian Zhang2,4, Sultan Pehlivan1, Maria-Elena Fernandez-Beros1,4, Lisette Umana4, Rachel Corona4, Sheila Smyth-Giambanco4, Sharon A Abbott4, Joan Reibman1,2,3,4.
Abstract
The destruction of the World Trade Center (WTC) towers on 11 September 2001 released many tons of aerosolized dust and smoke with potential for carcinogenic exposures to community members as well as responders. The WTC Environmental Health Center (WTC EHC) is a surveillance and treatment program for a diverse population of community members ("Survivors"), including local residents and workers, present in the NYC disaster area on 9/11 or in the days or weeks following. We report a case series of cancers identified in the WTC EHC as of 31 December 2019. Descriptive characteristics are presented for 2561 cancer patients (excluding non-melanoma skin cancer) and 5377 non-cancer WTC-EHC participants who signed informed consent. We identified a total of 2999 cancer diagnoses in 2561 patients: 2534 solid tumors (84.5%) and 465 lymphoid and hematopoietic tissue cancers (15.5%) with forty-one different cancer types. We describe the distribution, frequency, median age of cancer diagnosis and median latency from 9/11 by cancer site. In addition to common cancer types, rare cancers, including male breast cancers and mesotheliomas have been identified. The current study is the first report on cancer characteristics of enrollees at WTC EHC, a federally designated treatment and surveillance program for local community members affected by the 9/11 terrorist attack on the WTC.Entities:
Keywords: WTC survivors; World Trade Center; cancer; cancer characteristics; environmental exposure
Mesh:
Substances:
Year: 2020 PMID: 33019547 PMCID: PMC7578998 DOI: 10.3390/ijerph17197190
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1World Trade Center Environmental Health Center (WTC EHC) patients included in the WTC EHC cancer analysis as of 31 December 2019.
Characteristics of patients with/without cancers at enrollment in the WTC EHC.
| Non-Cancer | Cancer | ||
|---|---|---|---|
|
| 5377 | 2561 | |
|
| F | 2678 (49.8) | 1195 (46.7) |
| M | 2699 (50.2) | 1366 (53.3) | |
|
| 41.6 [0.0, 82.6] | 46.2 [0.0, 81.9] | |
|
| ≤20 | 309 (5.7) | 28 (1.1) |
| 21–29 | 613 (11.4) | 169 (6.6) | |
| 30–39 | 1454 (27.0) | 510 (19.9) | |
| 40–49 | 1781 (33.1) | 913 (35.7) | |
| 50–59 | 963 (17.9) | 755 (29.5) | |
| 60–69 | 202 (3.8) | 172 (6.7) | |
| 70–79 | 50 (0.9) | 13 (0.5) | |
| ≥80 | 5 (0.1) | 1 (0.0) | |
|
| Hispanic | 1592 (30.3) | 246 (11.8) |
| NH *-White | 1992 (37.9) | 1099 (52.9) | |
| NH *-Black | 1051 (20.0) | 394 (19.0) | |
| Asian | 610 (11.6) | 334 (16.1) | |
| Native American | 14 (0.3) | 3 (0.1) | |
|
| Normal weight (<25) | 1365 (28.7) | 486 (30.3) |
| Overweight (25–30) | 1717 (36.1) | 616 (38.4) | |
| Obese (≥30) | 1671 (35.2) | 504 (31.4) | |
|
| ≤$30,000/year | 2842 (54.8) | 860 (42.4) |
| >$30,000/year | 2340 (45.2) | 1169 (57.6) | |
|
| High school or less | 1801 (33.5) | 578 (27.3) |
| More than high school | 3572 (66.5) | 1541 (72.7) | |
|
| |||
|
| No | 2506 (47.0) | 1018 (48.1) |
| Yes | 2824 (53.0) | 1098 (51.9) | |
|
| Local Worker | 2766 (51.6) | 1352 (64.0) |
| Clean-up worker | 619 (11.5) | 17 (0.8) | |
| Other | 516 (9.6) | 95 (4.5) | |
|
| Never (≤1 p-y ***) | 3661 (69.2) | 1363 (65.0) |
| Former (>1 p-y) | 1076 (20.3) | 621 (29.6) | |
| Current (>1 p-y) | 555 (10.5) | 114 (5.4) | |
|
| ≤5 p-y | 4167 (78.7) | 1513 (72.1) |
| >5 p-y | 1125 (21.3) | 585 (27.9) | |
* NH: non-Hispanic, ** the unit for BMI is kg/m2, *** p-y: pack year.
Distribution of primary cancer diagnoses per cancer patient.
| Number of Cancers | n | Percent (%) |
|---|---|---|
|
| 2226 | 86.90 |
|
| 299 | 11.70 |
|
| 31 | 1.20 |
|
| 4 | 0.20 |
|
| 1 | 0.04 |
|
| 2561 | 100 |
Figure 2Distribution of solid, lymphoid and hematopoietic tissue cancer diagnoses in the WTC EHC (MPN = myeloproliferative neoplasms; MDS = myelodysplastic syndromes).
Figure 3Frequency of top fifteen cancer diagnoses in both sexes.
Figure 4Frequency of top fifteen solid cancer diagnoses in female (A) and male (B) patients.
Figure 5Frequency of cancers of lymphoid and hematopoietic tissue in female and male patients in WTC EHC (MPN = myeloproliferative neoplasms; MDS = myelodysplastic syndromes).
The median age of diagnosis and median latency in years from 9/11 distribution for top fifteen cancer and mesothelioma in male and female in the WTC EHC.
| All (n = 2999) | Male (n = 1623) | Female (n = 1376) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer Type | n (%) | Median Age of Diagnosis (Range) (Year) | Median Latency (Range) (Year) | n (%) | Median Age of Diagnosis (Range) (Year) | Median Latency (Range) (Year) | n (%) | Median Age of Diagnosis (Range) (Year) | Median Latency |
| Breast | 646 (22) | 55 (27, 86) | 12.4 (3.3, 17.8) | 11 (1) | 58 (41, 82) | 11.5 (4.7, 16.6) | 635 (46) | 55 (27, 86) | 12.4 (3.3, 17.8) |
| Prostate | 494 (16) | 62 (40, 83) | 12.3 (3.9, 18.2) | 494 (30) | 62 (40, 83) | 12.3 (3.9, 18.2) | |||
| Lung | 263 (9) | 64 (34, 89) | 14 (3.3, 18.1) | 111 (7) | 66 (38, 89) | 14.4 (5.3, 18.1) | 152 (11) | 63 (34, 85) | 13.7 (3.3, 18.1) |
| Thyroid | 223 (7) | 52 (13, 80) | 11.8 (2.7, 17.9) | 95 (6) | 52 (22, 75) | 12.4 (2.7, 17.7) | 128 (9) | 49 (13, 80) | 11.4 (3.0, 17.9) |
| Lymphoma | 217 (7) | 57 (21, 91) | 12 (0.9, 17.8) | 130 (8) | 56 (21, 82) | 11.8 (1.5, 17.5) | 87 (6) | 59 (22, 91) | 12.7 (0.9, 17.8) |
| Colon and rectum | 159 (5) | 59 (29, 84) | 13.4 (4.1, 18.1) | 101 (6) | 59 (36, 84) | 13.7 (4.1, 18.1) | 58 (4) | 59 (29, 82) | 12.4 (4.9, 17.2) |
| Head and neck sites | 141 (5) | 58 (26, 87) | 12.9 (3.6, 18.1) | 110 (7) | 58 (37, 87) | 11.9 (3.6, 18.1) | 31 (2) | 57 (26, 73) | 13.2 (7.7, 17.1) |
| Kidney | 112 (4) | 58 (7, 80) | 12.8 (4.2, 17.7) | 85 (5) | 58 (7, 80) | 12.7 (4.2, 17.7) | 27 (2) | 58 (32, 73) | 13.2 (6.4, 17.6) |
| Leukemia | 111 (4) | 59 (16, 81) | 12.4 (0.7, 16.8) | 81 (5) | 59 (16, 81) | 12.2 (0.7, 16.7) | 30 (2) | 58 (34, 72) | 12.6 (2.1, 16.8) |
| Myeloma | 104 (3) | 60 (28, 82) | 13.9 (3.9, 17.8) | 61(4) | 59 (28, 79) | 13.2 (5.2, 17.8) | 43 (3) | 60 (40, 82) | 14.3 (3.9, 17.7) |
| Melanoma of the skin | 89 (3) | 59 (34, 85) | 12.7 (3.2, 17.6) | 65 (4) | 60 (37, 85) | 12.8 (3.2, 17.6) | 24 (2) | 55 (34, 74) | 9.7 (4.2, 16.9) |
| Urinary bladder | 86 (3) | 65 (34, 95) | 13.2 (4.2, 17.4) | 72 (4) | 65 (34, 95) | 13.3 (4.2, 17.4) | 14 (1) | 64 (35, 75) | 12.2 (6.6, 16.8) |
| Gonad (Testis/Ovary) | 49 (2) | 52 (28, 82) | 12.2 (4.3, 17.6) | 20 (1) | 41 (28, 70) | 8.8 (4.3, 16.9) | 29 (2) | 57 (28, 82) | 13.1 (8.2, 17.6) |
| Stomach | 46 (2) | 59 (39, 75) | 13.8 (4.4, 17.8) | 31 (2) | 57 (39, 72) | 13.9 (4.4, 17.8) | 15 (1) | 60 (49, 75) | 12.4 (4.4, 17.0) |
| Pancreas | 44 (1) | 64 (46, 83) | 14.8 (5.7, 17.7) | 28 (2) | 64 (49, 83) | 14.9 (6.9, 17.7) | 16 (1) | 60 (46, 79) | 14.2 (5.7, 17.5) |
| Mesothelioma | 3 (0) | 57 (38, 70) | 15.4 (15.0, 16.7) | 2 (0) | 54 (38, 70) | 16 (15.4, 16.7) | 1 (0) | 57 (57, 57) | 15 (15.0, 15.0) |